Idexx Laboratories

IDEXX Laboratories to Release 2024 First Quarter Financial Results

Retrieved on: 
Thursday, April 4, 2024
Consumer, Health, Pets, Veterinary, Health Technology, Telephone, Webcast, IDXX, Idexx Laboratories, Laboratory

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens.
  • The Company will conduct an analyst conference call beginning at 8:30 a.m.
  • Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors .
  • To listen to the live conference call, please dial 1-800-776-0420 or 1-773-305-6837 and reference passcode 951825.

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Productivity, Oversight Committee, Elanco, Innovation, Growth, Abbott Laboratories, Trupanion, Strategic planning, Idexx Laboratories, Laboratory, ELAN, Fortification, Management

GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.

Key Points: 
  • New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee
    GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.
  • Ms. Turner brings significant global experience in both the animal health and broader healthcare industries.
  • Mr. Wallace is a well-respected animal health leader with more than 30 years of executive experience at companies such as Fort Dodge Animal Health, Trupanion and Ceva.
  • "We are pleased to welcome Kathy and Craig, both accomplished animal health industry executives, to the Elanco Board," said Jeff Simmons, President and CEO of Elanco Animal Health.

Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health

Retrieved on: 
Thursday, February 29, 2024
Professional Services, Finance, Investment, IDXX, Stewart Information Services Corporation, Trupanion, Organization, Animal, National Commission, Annual general meeting, Veterinarian, PACR, Oregon Tool, Laboratory, ELAN, Nutrition, Idexx Laboratories, EFN, CHRW, Abbott Laboratories, Relational Investors, Acquisition, Economic development, Livestock, STC, Pig, TSX, Pension, Fortification, Audit committee, HIL, Movement, Credit, Management

Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the Company’s insular Board and unaccountable CEO.

Key Points: 
  • Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the Company’s insular Board and unaccountable CEO.
  • Previously served on the Executive Leadership Team of Health for Animals, an organization that focuses on animal health products and animal well-being, and the Nutrition and Technology Innovation Advisory Board of Kiasco Animal Health, an animal health event series that connects innovation and investments.
  • Mr. Wallace is an experienced animal health and veterinary executive, most recently leading one of the largest animal health companies in the world.
  • Former Chief Executive Officer (North America/Pacific) of Ceva Santé Animale, the fifth largest animal health company worldwide.

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

Retrieved on: 
Tuesday, February 20, 2024
Veterinary, Software, Pets, Health, Medical Devices, Health Technology, Technology, Consumer, EST, Idexx Laboratories, IDXX, Doctor of Philosophy, Conference, Laboratory

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:
    Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit.
  • Monday, March 4, 11:00 am – 11:30 am EST – Jay Mazelsky, President and Chief Executive Officer, will present at the 45th Annual Raymond James Institutional Investors Conference.
  • Individuals can access the live audio webcasts of the presentations through links on the IDEXX website, www.idexx.com/investors .
  • An archived edition of the presentations will be available via the same link.

IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

Retrieved on: 
Thursday, February 15, 2024
Online, Pet, Idexx Laboratories, IDXX, Communication, Conference, Laboratory, Medical imaging

WESTBROOK, Maine, Feb. 15, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of Vello, a software solution that seamlessly connects veterinary practices and clients through modern, digital tools. As the only pet owner engagement solution purpose-built for IDEXX practice management software, Vello enables veterinary practices using ezyVet®, Neo®, and Cornerstone® software to communicate efficiently with pet owners in a single, easy-to-use system. With software-supported engagement across the life stages of a pet, pet owners become informed partners in care—supporting better health outcomes. IDEXX's Vello solution will be available as a new subscription service for ezyVet, Neo, and Cornerstone software in the U.S. in March 2024 and Canada in Q2.

Key Points: 
  • As the only pet owner engagement solution purpose-built for IDEXX practice management software, Vello enables veterinary practices using ezyVet®, Neo®, and Cornerstone® software to communicate efficiently with pet owners in a single, easy-to-use system.
  • With software-supported engagement across the life stages of a pet, pet owners become informed partners in care—supporting better health outcomes.
  • Now, Vello software allows practices to engage with pet owners pre- and post-visit through an intuitive solution purpose-built for their practice management software.
  • Online scheduling that enables pet owners to conveniently request appointments directly from health service reminders or through the Vello software.

Global Veterinary Rapid Test Kits Outlook Report 2023-2028: Market to Surge at 8.53% CAGR, Propelled by Advancements in Point of Care Testing and Expanding Pet Ownership - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 7, 2024
Health, Veterinary, Pets, Consumer, Growth, Human, Environment, Prevalence, Dog, Zoonosis, Ecosystem, Investment, Point-of-care testing, Animal, Pithing, Diabetes, Laboratory, POCT, Infection, Cat, Allergy, Idexx Laboratories, Cancer, Pet, Livestock

The "Veterinary Rapid Test Kits Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Rapid Test Kits Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The veterinary rapid test kits market is exhibiting considerable growth, with projections to expand at a compelling CAGR of 8.53% between 2022 and 2028.
  • The veterinary rapid test kits market is a testament to the advancing frontiers in animal health diagnostics.
  • Rapidly soaring pet ownership rates are catalyzing the demand for veterinary rapid test kits.

IDEXX Announces Fourth Quarter and Full Year Results

Retrieved on: 
Monday, February 5, 2024
Health, Medical Devices, Consumer, Technology, Software, Pets, Veterinary, EPS, Growth, International, Water, LPD, Idexx Laboratories, Investment, IDXX, CAG, Laboratory

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.
  • Earnings per diluted share (“EPS”) were $2.32 for the fourth quarter, an increase of 13% as reported and 17% on a comparable basis.
  • Results reflect operating margin contraction of 10 basis points as reported and expansion of 60 basis points on a comparable basis.
  • Fourth quarter EPS included $0.04 per share negative impact from currency changes and $0.02 per share in tax benefits from share-based compensation.

Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors

Retrieved on: 
Thursday, January 25, 2024
Medical Devices, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Engineering, Wolters Kluwer, IDXX, Research, Chairperson, CFO, Chemical engineering, Rutgers University, Laboratory, IBM, Rams Club, MBA, Cornell University, Merck & Co., Purdue University, Villanova University, Electricity, Organization, IBM Research, Idexx Laboratories, PARC, IEEE, Management

Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024.

Key Points: 
  • Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024.
  • “I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the board.
  • Mike joins our board with a wealth of experience in developing and implementing strategic and operational initiatives for complex global enterprises.
  • She is also a member of the Board of Directors of IDEXX Laboratories (IDXX), Inari Agriculture , and Wolters Kluwer N.V.

IDEXX Laboratories to Release 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Tuesday, January 23, 2024
Veterinary, Software, Pets, Health, Medical Devices, Health Technology, Technology, Consumer, Telephone, IDXX, Idexx Laboratories, Laboratory, Webcast

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens.
  • The Company will conduct an analyst conference call beginning at 8:30 a.m.
  • Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2023 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors .
  • To listen to the live conference call, please dial 1-800-776-0420 or 1-773-377-9037 and reference passcode 764284.

IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years

Retrieved on: 
Friday, January 12, 2024
Patient, IDXX, Idexx Laboratories, Infection, Parasitism, Weight loss, Dehydration, Dog, Laboratory, Pet, Workflow, Companion Animal Parasite Council, Cat, Diarrhea, CAPC, Veterinarian, Vaccine

WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora. The launch of Fecal Dx antigen testing with Cystoisospora is planned for March in North America and globally in Q3 2024, available at IDEXX Reference Laboratories.

Key Points: 
  • IDEXX's Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora.
  • The launch of Fecal Dx antigen testing with Cystoisospora is planned for March in North America and globally in Q3 2024, available at IDEXX Reference Laboratories.
  • "We are thrilled to announce the second expansion of the Fecal Dx antigen testing platform in less than two years, reinforcing our commitment to continuous innovation," said Jay Mazelsky, President and Chief Executive Officer of IDEXX.
  • Cystoisospora will automatically be included in Fecal Dx antigen testing panels and profiles at the time of launch with no additional charge to customers.